BioSpecifics Technologies (BSTC) PT Set at $65.00 by HC Wainwright
HC Wainwright set a $65.00 price target on BioSpecifics Technologies (NASDAQ:BSTC) in a research report report published on Tuesday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
Other equities research analysts also recently issued research reports about the stock. Zacks Investment Research downgraded shares of BioSpecifics Technologies from a buy rating to a hold rating in a research report on Friday, January 12th. lowered their price objective on shares of BioSpecifics Technologies from $72.00 to $65.00 and set a buy rating for the company in a research report on Wednesday, November 15th.
Shares of BioSpecifics Technologies (BSTC) opened at $43.44 on Tuesday. The firm has a market cap of $312.16, a PE ratio of 27.31 and a beta of 1.55. BioSpecifics Technologies has a 1 year low of $38.05 and a 1 year high of $58.79.
BioSpecifics Technologies Company Profile
BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.
Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with MarketBeat.com's FREE daily email newsletter.